SAN FRANCISCO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) --
Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s (PD) and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Chief Executive Officer, will present results of the company’s DJ-1 protein targeting small molecule pharmacological chaperone therapeutic programs at two conferences: the 4th World Parkinson’s Congress in Portland, Oregon on September 20-22; and, the 3rd International Parkinson’s Disease Symposium in Luxemburg on October 6-8.
DJ-1 is one of the key proteins involved in the prevention and reduction of damage due to oxidative stress and protein misfolding in brain cells. Loss of DJ-1 protein function has been linked to the onset and progression of familial and sporadic PD and other neurodegenerative diseases. Rescuing cells from the loss of DJ-1 function could be a critical factor in progressing towards a viable treatment of PD.
The presentations will describe the chemical microarray based high throughput binding screening applied for the identification of a diverse set of novel DJ-1 small molecule ligands, and characterization of one class of small molecule ligands and their positive biological activity in cellular and in vivo models of PD.
Key findings to be presented include that Cantabio’s novel DJ-1 targeting compound:
- Significantly increased life span of Drosophila melanogaster treated with paraquat, an in vivo oxidative stress model;
- Reduced neuroblastoma cell toxicity and dopaminergic neuronal loss mediated by paraquat treatment;
- Rescued rotenone-treated neuronal differentiated mesenchymal stem cells from toxicity, reactive oxygen species accumulation, caspase-3 activation, and mitochondrial membrane potential dysfunction.
The data will be presented at:
4th World Parkinson’s Congress, Portland, Oregon, USA
September 22, 11:30 -13:30 PST – Room: Exhibit Hall B, Level 1, Poster Board Number P04.09.
A poster presentation will be delivered, titled, “Identification of novel biologically active DJ-1 small molecule modulators with activity in cellular and in vivo models of oxidative stress relevant to Parkinson’s disease”
3rd International Parkinson’s Disease Symposium, Luxemburg, Europe
October 7, 12:15 - 13:30 CET- A poster presentation will be delivered, titled, “Identification of novel biologically active DJ-1 targeting small molecule modulators with protective activity in neuron and in vivo models of oxidative stress relevant to Parkinson’s disease”
The presentations’ lead author is Cantabio Pharmaceuticals, with co-authoring by researchers at Purdue University (USA), Novalix SAS (France), University of Antioquia (Colombia), and the Hungarian Academy of Sciences and University of Szeged (Hungary).
About Cantabio Pharmaceuticals, Inc.
Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. More information is available at www.cantabio.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Company contact: Thomas Sawyer, Ph.D., M.B.A. COO Cantabio Pharmaceuticals, Inc. 844-200-CTBO firstname.lastname@example.org Investors and Media Relations: Alex Fudukidis Russo Partners, LLC 646-942-5632 email@example.com
Source:Cantabio Pharmaceuticals Inc.